The S&P 500 futures currently trade four points below fair value.
CNBC reports that Novo Nordisk (NVO 47.67, -0.59, -1.2%) will lower the price of its Wegovy and Ozempic drugs to $349 per month from $499 per month for cash-paying direct-to-consumer customers.
Just released, the Empire State Manufacturing Index expanded to 18.7 in November (Briefing.com consensus 6.1) from a prior reading of 10.7.